AstraZeneca Pharma India Limited (ASTRAZEN) AI Stock Analysis

• Market Cap: ₹220.48B
• Dividend Yield: 0.36%
• Average Volume (3M): 911.00
• Price to Earnings (P/E): 120.2
• Beta (1Y): 0.71
• Revenue Growth: 33.69%
• EPS Growth: 91.28%
• Country: IN
• Employees: 940
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 22.33
• Shares Outstanding: 25,000,000
• 10 Day Avg. Volume: 722
• 30 Day Avg. Volume: 911
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹9,569.00
• Price Target Upside: 8.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹9,569.00 ▲(8.50% Upside)

AstraZeneca Pharma India Limited's strong financial performance, characterized by robust revenue growth and cash flow management, is the primary driver of its stock score. However, technical indicators present a mixed picture, and the high P/E ratio suggests potential overvaluation, which tempers the overall score.

AstraZeneca Pharma India Limited Business Overview & Revenue Model

Company Description

AstraZeneca Pharma India Limited (ASTRAZEN) is a leading biopharmaceutical company engaged in the development, manufacture, and commercialization of prescription medicines. It operates primarily in the healthcare and pharmaceuticals sector, focusing on key therapeutic areas such as oncology, cardiovascular, renal, and metabolic diseases. The company is a subsidiary of AstraZeneca PLC, a global biopharmaceutical company headquartered in the United Kingdom, and leverages its parent company's research and development capabilities to bring innovative treatments to the Indian market.

How the Company Makes Money

AstraZeneca Pharma India Limited generates revenue through the sale of its pharmaceutical products across various therapeutic areas. The company's revenue streams include the sale of prescription medications to hospitals, clinics, and pharmacies throughout India. As a subsidiary of AstraZeneca PLC, it benefits from a robust pipeline of innovative drugs and treatments developed through significant investment in research and development by its parent company. Key revenue drivers include the introduction of new drugs, expansion into new markets, and strategic partnerships or alliances with healthcare providers and government bodies to enhance market access and distribution. Additionally, AstraZeneca Pharma India may engage in licensing agreements or collaborations that contribute to its revenue.

AstraZeneca Pharma India Limited Financial Statement Overview

Summary

AstraZeneca Pharma India Limited showcases robust financial health with consistent revenue growth and strong cash flow management. The company maintains a stable balance sheet with minimal leverage and a solid equity base. Despite a decrease in net profit margins and return on equity in recent years, the overall financial performance remains commendable, driven by strong operating efficiencies and cash generation capabilities.

Income Statement

AstraZeneca Pharma India Limited has demonstrated a strong revenue growth trajectory with a notable increase in Total Revenue from ₹8,056 million in 2022 to ₹17,162 million in 2025, marking consistent annual growth. The Gross Profit Margin remains robust, improving from 55.6% in 2022 to 43.9% in 2025. EBIT and EBITDA Margins are stable with EBIT Margin at 12.5% and EBITDA Margin at 11.5% in 2025, highlighting operational efficiency. However, the Net Profit Margin decreased from 12.3% in 2024 to 6.7% in 2025 due to rising operational costs.

Balance Sheet

The company maintains a strong equity base with Stockholders' Equity increasing from ₹5,113.9 million in 2022 to ₹7,703.5 million in 2025. The Debt-to-Equity Ratio is low at 0.05 in 2025, indicating low financial leverage. The Equity Ratio improved to 50.7% in 2025, reflecting a stable financial position. However, Total Liabilities have increased over time, which could pose a risk if not managed properly. Return on Equity (ROE) decreased from 22.7% in 2022 to 15.0% in 2025, requiring attention.

Cash Flow

The company exhibits strong cash flow management, with Free Cash Flow growing significantly from ₹911.8 million in 2022 to ₹636.1 million in 2025. The Operating Cash Flow to Net Income Ratio improved to 0.56 in 2025, indicating efficient conversion of income into cash. The company's ability to generate sufficient cash flow to cover its capital expenditures and operating needs is a positive financial indicator.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.19B	17.16B	12.96B	10.03B	8.06B	8.09B
Gross Profit	5.75B	7.53B	6.95B	5.78B	4.48B	4.78B
EBITDA	1.59B	1.98B	2.36B	1.51B	1.01B	1.48B
Net Income	969.69M	1.16B	1.62B	992.90M	616.00M	933.00M
Balance Sheet
Total Assets	0.00	15.18B	10.78B	9.85B	8.57B	7.75B
Cash, Cash Equivalents and Short-Term Investments	4.97B	5.53B	5.06B	5.11B	4.48B	3.52B
Total Debt	0.00	357.30M	45.90M	72.14M	86.30M	121.40M
Total Liabilities	-6.79B	7.48B	3.66B	3.96B	3.45B	3.19B
Stockholders Equity	6.79B	7.70B	7.12B	5.89B	5.11B	4.56B
Cash Flow
Free Cash Flow	0.00	636.10M	171.10M	497.70M	911.80M	970.70M
Operating Cash Flow	0.00	653.60M	278.70M	582.90M	1.01B	1.05B
Investing Cash Flow	0.00	308.00M	217.40M	181.10M	47.40M	1.73B
Financing Cash Flow	0.00	-655.90M	-443.80M	-244.80M	-94.60M	-89.70M

AstraZeneca Pharma India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8819.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Negative. The current price of 8819.1 is below the 20-day moving average (MA) of 8978.71, below the 50-day MA of 8836.52, and above the 200-day MA of 8163.70, indicating a neutral trend. The MACD of 28.87 indicates Positive momentum. The RSI at 47.88 is Neutral, neither overbought nor oversold. The STOCH value of 39.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTRAZEN.

AstraZeneca Pharma India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKEM	72 Outperform	₹648.75B	28.40	18.07%	0.83%	4.49%	11.22%
ASTRAZEN	67 Neutral	₹220.48B	120.24	―	0.36%	33.69%	91.28%
GLAXO	66 Neutral	₹452.43B	47.61	47.54%	2.02%	6.65%	48.47%
GLENMARK	54 Neutral	₹556.02B	73.77	11.83%	0.13%	10.99%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

AstraZeneca Pharma India Limited Corporate Events

AstraZeneca Pharma India Confirms Regulatory Compliance

AstraZeneca Pharma India Limited has submitted a compliance certificate to the stock exchanges, confirming adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This announcement underscores the company’s commitment to regulatory compliance, which is crucial for maintaining investor trust and ensuring smooth operations within the financial markets.

AstraZeneca Pharma India Sets Record Date for Final Dividend

AstraZeneca Pharma India Limited has announced that the record date for determining shareholders’ entitlement to the final dividend for the financial year 2024-25 is set for July 18, 2025. The final dividend, pending shareholder approval, is scheduled to be paid or dispatched by September 12, 2025, reflecting the company’s commitment to returning value to its shareholders.